Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
HBM Holdings Ltd. ( (HK:2142) ) has shared an announcement.
HBM Holdings Limited has exercised a warrant obtained under its license and collaboration agreement between its incubated biotech unit HBM Alpha Therapeutics and U.S.-based Spruce Biosciences Inc., converting it into an equity stake in the partner company. Following the warrant exercise on 19 January 2026, HBM now holds approximately 3.8% of Spruce’s total outstanding shares and about 3.1% on a fully diluted basis, a move that deepens the strategic alignment between the parties but is small enough that it does not trigger Hong Kong Listing Rules reporting, announcement or shareholder approval requirements, indicating limited immediate financial impact while reinforcing HBM’s long-term collaborative position in hormone-related therapeutics.
The most recent analyst rating on (HK:2142) stock is a Hold with a HK$15.00 price target. To see the full list of analyst forecasts on HBM Holdings Ltd. stock, see the HK:2142 Stock Forecast page.
More about HBM Holdings Ltd.
HBM Holdings Limited is a Cayman Islands-incorporated holding company focused on innovative biotechnology, operating through subsidiaries such as HBM Alpha Therapeutics (HBMAT), which develops novel therapies targeting corticotropin-releasing hormone for various disorders. The group positions itself in the biopharmaceutical sector through licensing, collaboration agreements and incubation of drug development ventures aimed at addressing unmet medical needs.
Average Trading Volume: 4,552,252
Technical Sentiment Signal: Buy
Current Market Cap: HK$12.7B
See more insights into 2142 stock on TipRanks’ Stock Analysis page.